SURPASS programme

What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to know what…

On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…

Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. A question about dual agonism that I think has a definite…

Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…

The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about 2.5 mg starting dose that I…

Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1…

Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? The question about Tirzepatide molecular mass that…

Posting this under the heading it deserves: Reading SURMOUNT-1 without the press release Everything below is what sits behind that. What changes if the standard account of reading SURMOUNT-1 without the press…

Asking directly, because I could not find a straight answer: Why tirzepatide titration schedules have more steps than semaglutide's I have spent a fortnight trying to pin tirzepatide titration schedules down…

On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. A narrow question about Tirzepatide in type 2…

On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…

Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here…

Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Asking about tirzepatide and nausea directly, because I…

Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? A question about dual agonism that I think has a definite answer, unlike most of what I…

Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…

The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. I would like to know…

SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…

Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. Tirzepatide molecular mass keeps being re-asked here…

Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…

Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…

SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about SURPASS-2.…

The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about…

Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…